Biotech news on June 22, 2026

1. 0115:45 UTC

   Gut researchers say microbiome product claims outpace evidence

   5 outlets · first: houstonpublicmedia.org Clinical trial

   Machine summary Gut researchers say that in many cases what is being promoted about testing, resetting or optimizing the gut microbiome has leapfrogged the evidence, according to reports.

   1. Gut researchers say that in many cases, what's being promoted about the microbiome has leapfrogged the evidence, according to the reports.

   Reported by houstonpublicmedia.org, wutc.org, wvtf.org, kios.org and NPR.

2. 0214:45 UTC

   Cogent Biosciences presents preclinical data for CGT1145

   2 outlets · first: finance.yahoo.com Clinical trial

   Reported by finance.yahoo.com and Insider Monkey.

   • Cogent Biosciences
   • CGT1145

   Full coverage: every report, when each was published, and who was named (2 outlets)

3. 0309:45 UTC

   Nigeria Lassa fever deaths reach 214, NCDC says

   2 outlets · first: allafrica.com

   Machine summary Nigeria's Centre for Disease Control and Prevention reported 214 Lassa fever deaths and a case fatality rate of 25.0 per cent in its Week 23 situation report covering June 1 to June 7, 2026.

   1. The NCDC reported 214 Lassa fever deaths and a case fatality rate of 25.0 per cent, according to its Week 23 situation report for June 1 to June 7.
   2. The NCDC said the case fatality rate rose from 18.9 per cent in the same period in 2025.
   3. The NCDC said the National Lassa fever multi-partner, multi-sectoral Incident Management System remained activated to coordinate the response.

   Reported by allafrica.com and pmnewsnigeria.com.

   • Nigeria Centre for Disease Control (NCDC)
   • Incident Management System (IMS)

4. 0403:45 UTC

   Aurobindo Pharma US gets FTC nod for $250 million Lannett acquisition

   2 outlets · first: economictimes.indiatimes.com Pharma

   Machine summary Key facts from the reports:

   1. Swami S. Iyer, CEO of Aurobindo Pharma USA, said the acquisition accelerates revenue growth, strengthens US-based manufacturing capabilities, and enhances the company's position in complex, non-opioid controlled substances.
   2. Tim Crew, Lannett Company's CEO, said Aurobindo's market reach and resources will help make Lannett's portfolio of medicines more affordable and accessible for patients.

   Reported by economictimes.indiatimes.com and moneycontrol.com.

   • Aurobindo Pharma Ltd.
   • Aurobindo Pharma USA, Inc.
   • Lannett Company LLC

Each summary and its key facts are a machine summary of the reports linked under it; the outlets, times and counts come from those reports' own records. How a rundown is built.